Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Lineage Cell Therapeutics, Inc. (LCTX) had Return on Tangible Equity of -640.59% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$2.77M |
|
$-30.46M |
|
$0.04M |
|
$2.73M |
|
$22.55M |
|
$-19.78M |
|
$-10.58M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
$-19.78M |
|
$-4.86M |
|
228.36M |
|
228.36M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$43.84M |
|
$2.25M |
|
$46.95M |
|
$90.80M |
|
$10.76M |
|
$0.05M |
|
$32.93M |
|
$43.69M |
|
$47.11M |
|
$4.74M |
|
$47.11M |
|
228.36M |
|
| Cash Flow Statement Financials | |
$-10.43M |
|
$1.89M |
|
$4.74M |
|
$46.35M |
|
$42.77M |
|
$-3.58M |
|
$2.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.08 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
98.59% |
|
-715.37% |
|
-715.37% |
|
-- |
|
-1098.16% |
|
-1101.77% |
|
$-10.54M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
10.80 |
|
8.33 |
|
-64.45% |
|
|
Return on Tangible Equity |
-640.59% |
-33.44% |
|
-64.39% |
|
$0.21 |
|
$-0.05 |
|
$-0.05 |
|